Company News
Biohaven Shares Surge 8.5% on Trial Wins
Biohaven shares jumped 8.5% after positive Phase 1b data for BHV-1300 and BHV-1400 targeting Graves’ disease and IgA nephropathy.
BHV-1300 reduced pathogenic TSHR‑IgG1 autoantibodies >80% over 12 week
